Details of the Drug

General Information of Drug (ID: DMUL45H)

Drug Name
Naltrexone
Synonyms
Depotrex; Naltrel; Vivitrex; Vivitrol; Naltrexone Depot; IBS therapy, Pain Therapeutics; Irritable bowel syndrome therapy, Pain Therapeutics; PTI-901; XR-NTX; Naltrexone (sustained release), DAS; Naltrexone (sustained release), elbion; Naltrexone depot (injectable suspension), DrugAbuse Sciences; Naltrexone depot (injectable suspension), elbion; Opioid antagonists (irritable bowel syndrome), Pain Therapeutics; Naltrexone (low-dose), Pain Therapeutics; Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek; Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma; Naltrexone (once-monthly controlled-release, Medisorb), Alkermes
Indication
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Approved [1]
Human immunodeficiency virus infection 1C62 Phase 4 [2], [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 341.4
Topological Polar Surface Area (xlogp) 1.9
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 57 mL/min/kg [5]
Elimination
1% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.9 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.43935 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.79% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 7.6 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 100 mg/mL [4]
Chemical Identifiers
Formula
C20H23NO4
IUPAC Name
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Canonical SMILES
C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
InChI
InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
InChIKey
DQCKKXVULJGBQN-XFWGSAIBSA-N
Cross-matching ID
PubChem CID
5360515
ChEBI ID
CHEBI:7465
CAS Number
16590-41-3
DrugBank ID
DB00704
TTD ID
D0PG8O
VARIDT ID
DR00968
INTEDE ID
DR1128
ACDINA ID
D00455

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor (OPR) TTN4QDT NOUNIPROTAC Antagonist [7], [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)
Main DME 		DEYGVN4 UD11_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Naltrexone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Disulfiram DMCL2OK Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Disulfiram. Substance abuse [6C40] [29]
Coadministration of a Drug Treating the Disease Different from Naltrexone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [30]
Tretinoin DM49DUI Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Tretinoin. Acne vulgaris [ED80] [29]
Isotretinoin DM4QTBN Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Isotretinoin. Acne vulgaris [ED80] [29]
Nicotinamide DMUPE07 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Nicotinamide. Acquired cutaneous blood vessel malformation [EF20] [29]
Pioglitazone DMKJ485 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Pioglitazone. Acute diabete complication [5A2Y] [29]
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Tagraxofusp. Acute myeloid leukaemia [2A60] [29]
Gilteritinib DMWQ4MZ Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Gilteritinib. Acute myeloid leukaemia [2A60] [29]
Inotersen DMJ93CT Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Inotersen. Amyloidosis [5D00] [29]
Dronedarone DMA8FS5 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Dronedarone. Angina pectoris [BA40] [29]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [31]
Oxymetholone DMFXUT8 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Oxymetholone. Aplastic anaemia [3A70] [29]
Posaconazole DMUL5EW Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Posaconazole. Aspergillosis [1F20] [29]
Zileuton DMVRIC2 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Zileuton. Asthma [CA23] [29]
Clavulanate DM2FGRT Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Clavulanate. Bacterial infection [1A00-1C4Z] [29]
Clarithromycin DM4M1SG Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Clarithromycin. Bacterial infection [1A00-1C4Z] [29]
Sulfamethoxazole DMB08GE Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [29]
Levofloxacin DMS60RB Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Levofloxacin. Bacterial infection [1A00-1C4Z] [29]
Troleandomycin DMUZNIG Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Troleandomycin. Bacterial infection [1A00-1C4Z] [29]
Minocycline DMVN5OH Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Minocycline. Bacterial infection [1A00-1C4Z] [29]
Telithromycin DMZ4P3A Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Telithromycin. Bacterial infection [1A00-1C4Z] [29]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Naltrexone and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [32]
Temozolomide DMKECZD Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Temozolomide. Brain cancer [2A00] [29]
Lomustine DMMWSUL Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Lomustine. Brain cancer [2A00] [29]
Lapatinib DM3BH1Y Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Lapatinib. Breast cancer [2C60-2C6Y] [29]
LY2835219 DM93VBZ Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and LY2835219. Breast cancer [2C60-2C6Y] [29]
Pralatrexate DMAO80I Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Pralatrexate. Breast cancer [2C60-2C6Y] [29]
Tucatinib DMBESUA Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Tucatinib. Breast cancer [2C60-2C6Y] [29]
Bosutinib DMTI8YE Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Bosutinib. Breast cancer [2C60-2C6Y] [29]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [29]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Fluoxymesterone. Breast cancer [2C60-2C6Y] [29]
Atorvastatin DMF28YC Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [29]
Fenofibric acid DMGO2MC Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [29]
Macitentan DMP79A1 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Macitentan. Cardiovascular disease [BA00-BE2Z] [29]
Chenodiol DMQ8JIK Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Chenodiol. Cholelithiasis [DC11] [29]
Phenylbutazone DMAYL0T Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Phenylbutazone. Chronic pain [MG30] [29]
Ketoprofen DMRKXPT Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ketoprofen. Chronic pain [MG30] [29]
Regorafenib DMHSY1I Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Regorafenib. Colorectal cancer [2B91] [29]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Intedanib. Colorectal cancer [2B91] [29]
Pasireotide DMHM7JS Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Pasireotide. Cushing syndrome [5A70] [29]
Ivacaftor DMZC1HS Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ivacaftor. Cystic fibrosis [CA25] [29]
Ethanol DMDRQZU Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ethanol. Cystitis [GC00] [29]
Nefazodone DM4ZS8M Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Nefazodone. Depression [6A70-6A7Z] [29]
Milnacipran DMBFE74 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Milnacipran. Depression [6A70-6A7Z] [29]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [29]
Felbamate DM1V5ZS Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Felbamate. Epilepsy/seizure [8A61-8A6Z] [29]
Fosphenytoin DMOX3LB Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [29]
Ethotoin DMXWOCP Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ethotoin. Epilepsy/seizure [8A61-8A6Z] [29]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Cannabidiol. Epileptic encephalopathy [8A62] [29]
Mefenamic acid DMK7HFI Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Mefenamic acid. Female pelvic pain [GA34] [29]
Dantrolene DM1D8XY Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Dantrolene. Fever [MG26] [29]
Itraconazole DMCR1MV Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Itraconazole. Fungal infection [1F29-1F2F] [29]
Terbinafine DMI6HUW Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Terbinafine. Fungal infection [1F29-1F2F] [29]
Ketoconazole DMPZI3Q Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ketoconazole. Fungal infection [1F29-1F2F] [29]
Atovaquone DMY4UMW Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Atovaquone. Fungal infection [1F29-1F2F] [29]
Sunitinib DMCBJSR Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Sunitinib. Gastrointestinal stromal tumour [2B5B] [29]
Lamivudine DMI347A Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Lamivudine. Hepatitis virus infection [1E50-1E51] [29]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [29]
Isoniazid DM5JVS3 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [29]
Rifampin DMA8J1G Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [29]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Brentuximab vedotin. Hodgkin lymphoma [2B30] [29]
Tipranavir DM8HJX6 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Emtricitabine DMBMUWZ Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Emtricitabine. Human immunodeficiency virus disease [1C60-1C62] [29]
Zalcitabine DMH7MUV Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [29]
Didanosine DMI2QPE Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Didanosine. Human immunodeficiency virus disease [1C60-1C62] [29]
Rilpivirine DMJ0QOW Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [29]
Abacavir DMMN36E Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Abacavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Darunavir DMN3GCH Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Darunavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Maraviroc DMTL94F Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [29]
Fluvastatin DM4MDJY Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Fluvastatin. Hyper-lipoproteinaemia [5C80] [29]
Fenofibrate DMFKXDY Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Fenofibrate. Hyper-lipoproteinaemia [5C80] [29]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Naltrexone and Mipomersen. Hyper-lipoproteinaemia [5C80] [33]
Rosuvastatin DMMIQ7G Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [29]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Naltrexone and Teriflunomide. Hyper-lipoproteinaemia [5C80] [34]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Naltrexone and BMS-201038. Hyper-lipoproteinaemia [5C80] [35]
Captopril DM458UM Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Captopril. Hypertension [BA00-BA04] [29]
Methyldopa DM5I621 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Methyldopa. Hypertension [BA00-BA04] [29]
Perindopril DMOPZDT Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Perindopril. Hypertension [BA00-BA04] [29]
Quinapril DMR8H31 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Quinapril. Hypertension [BA00-BA04] [29]
Lisinopril DMUOK4C Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Lisinopril. Hypertension [BA00-BA04] [29]
Tolvaptan DMIWFRL Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [29]
Bremelanotide DM20LIM Major Altered absorption of Naltrexone due to GI dynamics variation caused by Bremelanotide. Hypoactive sexual desire dysfunction [HA00] [36]
Pirfenidone DM6VZFQ Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Pirfenidone. Idiopathic interstitial pneumonitis [CB03] [29]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [29]
Febuxostat DMDEXQ0 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Febuxostat. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [29]
Meclofenamic acid DM05FXR Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [29]
Crizotinib DM4F29C Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Crizotinib. Lung cancer [2C25] [29]
Ceritinib DMB920Z Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ceritinib. Lung cancer [2C25] [29]
Lurbinectedin DMEFRTZ Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Lurbinectedin. Lung cancer [2C25] [29]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Alectinib. Lung cancer [2C25] [29]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and BIBW 2992. Lung cancer [2C25] [29]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Pralsetinib. Lung cancer [2C25] [29]
Capmatinib DMYCXKL Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Capmatinib. Lung cancer [2C25] [29]
Sulphadoxine DMZI2UF Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Sulphadoxine. Malaria [1F40-1F45] [29]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [29]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [29]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Idelalisib. Mature B-cell leukaemia [2A82] [37]
IPI-145 DMWA24P Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and IPI-145. Mature B-cell leukaemia [2A82] [29]
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Blinatumomab. Mature B-cell lymphoma [2A85] [29]
Mercaptopurine DMTM2IK Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Mercaptopurine. Mature B-cell lymphoma [2A85] [29]
Ponatinib DMYGJQO Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ponatinib. Mature B-cell lymphoma [2A85] [29]
Cytarabine DMZD5QR Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Cytarabine. Mature B-cell lymphoma [2A85] [29]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Arry-162. Melanoma [2C30] [29]
Vemurafenib DM62UG5 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Vemurafenib. Melanoma [2C30] [29]
Ipilimumab DMJTIYK Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ipilimumab. Melanoma [2C30] [29]
Dacarbazine DMNPZL4 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Dacarbazine. Melanoma [2C30] [29]
Danazol DML8KTN Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Danazol. Menstrual cycle bleeding disorder [GA20] [29]
Exjade DMHPRWG Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Exjade. Mineral absorption/transport disorder [5C64] [29]
Riluzole DMECBWN Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Riluzole. Motor neuron disease [8B60] [29]
Carfilzomib DM48K0X Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Carfilzomib. Multiple myeloma [2A83] [29]
Panobinostat DM58WKG Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Panobinostat. Multiple myeloma [2A83] [29]
Elotuzumab DMEYHG9 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Elotuzumab. Multiple myeloma [2A83] [29]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Tecfidera. Multiple sclerosis [8A40] [29]
Siponimod DM2R86O Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Siponimod. Multiple sclerosis [8A40] [29]
Fingolimod DM5JVAN Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Fingolimod. Multiple sclerosis [8A40] [29]
Ozanimod DMT6AM2 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ozanimod. Multiple sclerosis [8A40] [29]
Fedratinib DM4ZBK6 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Fedratinib. Myeloproliferative neoplasm [2A20] [29]
Nilotinib DM7HXWT Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Nilotinib. Myeloproliferative neoplasm [2A20] [29]
Bupropion DM5PCS7 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Bupropion. Nicotine use disorder [6C4A] [29]
Entrectinib DMMPTLH Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Entrectinib. Non-small cell lung cancer [2C25] [29]
Orlistat DMRJSP8 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Orlistat. Obesity [5B80-5B81] [29]
Etodolac DM6WJO9 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Etodolac. Pain [MG30-MG3Z] [29]
Ibuprofen DM8VCBE Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ibuprofen. Pain [MG30-MG3Z] [29]
Bromfenac DMKB79O Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Bromfenac. Postoperative inflammation [1A00-CA43] [29]
ABIRATERONE DM8V75C Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and ABIRATERONE. Prostate cancer [2C82] [29]
Bicalutamide DMZMSPF Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Bicalutamide. Prostate cancer [2C82] [29]
Ambrisentan DMD1QXW Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Ambrisentan. Pulmonary hypertension [BB01] [29]
Axitinib DMGVH6N Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Axitinib. Renal cell carcinoma [2C90] [29]
Meloxicam DM2AR7L Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Meloxicam. Rheumatoid arthritis [FA20] [29]
Tocilizumab DM7J6OR Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Tocilizumab. Rheumatoid arthritis [FA20] [29]
Oxaprozin DM9UB0P Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Oxaprozin. Rheumatoid arthritis [FA20] [29]
Flurbiprofen DMGN4BY Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Flurbiprofen. Rheumatoid arthritis [FA20] [29]
Sulfasalazine DMICA9H Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Sulfasalazine. Rheumatoid arthritis [FA20] [29]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Sarilumab. Rheumatoid arthritis [FA20] [29]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Naltrexone and Leflunomide. Rheumatoid arthritis [FA20] [34]
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [29]
PDX-101 DM6OC53 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and PDX-101. Solid tumour/cancer [2A00-2F9Z] [29]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [29]
LEE011 DMMX75K Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and LEE011. Solid tumour/cancer [2A00-2F9Z] [29]
Methyltestosterone DMWLFGO Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [29]
Fostamatinib DM6AUHV Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Fostamatinib. Thrombocytopenia [3B64] [29]
Eltrombopag DMOGFIX Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Eltrombopag. Thrombocytopenia [3B64] [29]
Lenvatinib DMB1IU4 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Lenvatinib. Thyroid cancer [2D10] [29]
Methimazole DM25FL8 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Methimazole. Thyrotoxicosis [5A02] [29]
Trimetrexate DMDEA85 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Trimetrexate. Toxoplasmosis [1F57] [29]
Elagolix DMB2C0E Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Elagolix. Uterine fibroid [2E86] [29]
Amiodarone DMUTEX3 Moderate Increased risk of hepatotoxicity by the combination of Naltrexone and Amiodarone. Ventricular tachyarrhythmia [BC71] [29]
⏷ Show the Full List of 146 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Cysteine hydrochloride E00318 25150 Antioxidant
D&C red no. 28 E00491 6097185 Colorant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
Erythrosine sodium anhydrous E00324 27872 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ascorbic acid E00579 54670067 Acidulant; Antioxidant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dibutyl sebacate E00160 7986 Plasticizing agent
Edetate disodium E00186 8759 Complexing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Gelatin E00630 Not Available Other agent
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Haematite red E00236 14833 Colorant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Ethyl cellulose E00699 Not Available Coating agent; Microencapsulating agent; Binding agent; Diluent; Viscosity-controlling agent
⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Naltrexone Hydrochloride 0.8mg extended release capsule 0.8mg Extended Release Capsule Oral
Naltrexone Hydrochloride 20mg extended release capsule 20mg Extended Release Capsule Oral
Naltrexone Hydrochloride 8mg extended release tablet 8mg Extended Release Tablet Oral
Naltrexone Hydrochloride 90mg extended release tablet 90mg Extended Release Tablet Oral
Naltrexone Hydrochloride 50mg tablet 50mg Tablet Oral
Naltrexone 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1639).
3 ClinicalTrials.gov (NCT02478489) Alcohol Use Disorder hOsPital Treatment Trial.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
8 In vivo chronic exposure to heroin or naltrexone selectively inhibits liver microsome formation of estradiol-3-glucuronide in the rat. Biochem Pharmacol. 2008 Sep 1;76(5):672-9.
9 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
10 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
11 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
12 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
13 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
14 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
15 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
16 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
17 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
18 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
19 Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
20 The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
22 Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
23 mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
24 Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
25 Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
26 Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
27 Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
28 Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
29 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
30 Cerner Multum, Inc. "Australian Product Information.".
31 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
32 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
33 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
34 Canadian Pharmacists Association.
35 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
36 Product Information. Vyleesi (bremelanotide). AMAG Pharmaceuticals Inc, Lexington, MA.
37 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.